Skip to content

Gastrografin in Postoperative Ileus

Randomised Double-blind Placebo-controlled Trial of Gastrografin in the Therapeutic Management of Prolonged Postoperative Ileus Following Elective Surgery.

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01648972
Acronym
GAP
Enrollment
Unknown
Registered
2012-07-25
Start date
2012-09-30
Completion date
2014-07-31
Last updated
2014-07-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prolonged Postoperative Ileus

Brief summary

After abdominal surgery there is a period of unavoidable dysfunction of the gut. During this time patients are often unable to eat and drink, and do not pass any flatus or stool. Though this resolves within a few days for most, there are a significant number (around 30%) who go on to have a prolonged period of this dysfunction known clinically as postoperative ileus. It has been clearly shown that this group of patients have worse health outcomes and spend a longer time in hospital. The aim of this study is to trial a drug - gastrografin - in the management of prolonged postoperative ileus. Gastrografin is safe, economical, readily available, and has been used with great success in the similar condition of bowel obstruction. It is predicted that gastrografin will shorten the duration of a prolonged postoperative ileus, thus affording affected patients a better outcome from surgery.

Interventions

DRUGPlacebo

Sponsors

University of Auckland, New Zealand
Lead SponsorOTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \> 18 years. * Current inpatient following elective laparoscopic or open surgery. * Classified as having prolonged postoperative ileus. * Able to understand risks/benefits of the study. * Able to give informed consent.

Exclusion criteria

* Pregnancy. * ASA of 4 or greater. * Previous allergic reaction to gastrografin or iodinated contrast agents. * Manifest hyperthyroidism.

Design outcomes

Primary

MeasureTime frame
Time from diagnosis (and administration of study drug) to resolution of prolonged postoperative ileus.

Secondary

MeasureTime frame
Length of hospital stay (days)Days

Countries

New Zealand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026